A Study of ICP-022 in Patients With R/R DLBCL

Key Inclusion criteria： 1. Men and women between 18 and 75 years old, 2. Histologically confirmed diffuse large B-cell lymphoma（DLBCL）with MyD88 L265P and CD79B positive, at least one measurable tumor of greater than 1.5 centimeter in long axis by contrast-enhanced CT/MRI, 3. ECOG performance status of 0-2, 4. Voluntary written informed consent prior to trail screening. Key Exclusion criteria: 1. History of other active malignancies, unless cured without evidence of relapse or metastasis within 5 years of study entry 2. History of Richter's syndrome 3. Current or history of lymphoma involved central nervous system 4. Prior corticosteroids (at dosages equivalent to prednisone \> 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation therapy, or antibody based therapies or anti-cancer TCM within 4 weeks of the start of study drug. 5. The investigator considers other conditions unsuitable for this study. Note: Other protocol defined Inclusion/Exclusion criteria may apply.